Improvement of pruritus with baricitinib in a patient with prurigo nodularis refractory to multiple biologic therapies.

Olumiant (baricitinib) - Eli Lilly

Improvement of pruritus with baricitinib in a patient with prurigo nodularis refractory to multiple biologic therapies. (PubMed, Eur J Dermatol) - Sep 1, 2026 - No abstract available
Journal • Dermatology • Immunology • Prurigo Nodularis • Pruritus

http://www.ncbi.nlm.nih.gov/pubmed/42671876

Ken Iozumi; Masako Yamamoto; Yoshihito Mima

Sep 1, 2026